Cargando…

A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes

INTRODUCTION: We report a case series of severe ketoacidosis after COVID-19 vaccination in a type 1 diabetes patients treated with insulin and an SGLT-2 inhibitor. CASE REPORT: We present two cases of type 1 diabetes mellitus. One patient was treated with insulin therapy and an SGLT-2 inhibitor, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakou, Fumiyoshi, Saburi, Masuo, Hirose, Ai, Akaoka, Hiroaki, Hirota, Yusuke, Kobayashi, Takaaki, Awane, Naoko, Asahi, Nobuteru, Amagawa, Toshihiro, Ozawa, Sachihiko, Ohno, Atsushi, Matsushita, Takaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971718/
https://www.ncbi.nlm.nih.gov/pubmed/35370952
http://dx.doi.org/10.3389/fendo.2022.840580
Descripción
Sumario:INTRODUCTION: We report a case series of severe ketoacidosis after COVID-19 vaccination in a type 1 diabetes patients treated with insulin and an SGLT-2 inhibitor. CASE REPORT: We present two cases of type 1 diabetes mellitus. One patient was treated with insulin therapy and an SGLT-2 inhibitor, and the other patient was treated with insulin therapy alone. Both patients became ill after coronavirus disease-2019 vaccination, making it difficult to continue their diet or insulin injections. On admission, they developed severe diabetic ketoacidosis. This is the first report of ketoacidosis after coronavirus disease-2019 vaccination. CONCLUSION: The vaccine should be carefully administered to type 1 diabetes patients receiving intensive insulin therapy and a sodium-glucose transporter due to the high risk ketoacidosis. It is important to instruct patients to drink sufficient fluids and to continue insulin injections when they become sick.